

VCN Biosciences announces that MINECO has granted funding for the project Cure4RB to clinically develop its lead candidate VCN-01 for the treatment of retinoblastoma.

A consortium led by VCN Biosciences receives funding for Cure4RB project (RTC-2015-4319-1) by Ministerio de Economía y Competitividad (MINECO) from Spanish Government, program RETOS DE COLABORACIÓN - 2015. This project aims to develop VCN-01 as a new clinical treatment for paediatric patients suffering from retinoblastoma, the most common ocular malignancy during childhood.

The consortium also involves research groups from Fundació Sant Joan de Deu (Barcelona), ICO (Institut Català d'Oncologia) and Laboratorios Reig Jofre SA that will work together to initiate clinical trials with VCN-01 in this indication during 2016.